Pacira BioSciences (FRA:82P) Beta: -0.3536 (As of Jun. 24, 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
74 GF Score
Price €20.60
GF Value €24.22
! 6 Warning Signs
View Full Analysis

What is Pacira BioSciences Beta?

Pacira BioSciences FRA:82P +6.74% 74 Beta is -0.3536 as of Jun. 24, 2026. GuruFocus rates FRA:82P with a GF Score™ of 74/100 and a GF Value™ of €24.22. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Pacira BioSciences's Beta is -0.3536.


Pacira BioSciences  (FRA:82P) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Pacira BioSciences Beta Related Terms


Pacira BioSciences Beta Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Beta Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.85 0.53 -0.80 -1.07

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.00 0.24 -1.07 -0.20

FRA:82P vs ETON, AMPH, ESPR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Beta distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Beta falls into.


FRA:82P
74GF Score
Pacira BioSciences Inc FRA:82P
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.3536 mean?
Pacira BioSciences (FRA:82P) has a Beta of -0.3536 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pacira BioSciences and its competitors.
Is Pacira BioSciences' Beta too high?
Pacira BioSciences' current Beta is -0.3536. Overall, Pacira BioSciences has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Beta compare to ETON and AMPH?
Pacira BioSciences' Beta of -0.3536 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Pacira BioSciences and its competitors. Pacira BioSciences's current Beta is -0.3536. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Beta of -0.3536. The stock's GF Value™ is €24.22, compared to a current price of €20.60 — trading 14.9% below its estimated fair value. The current Beta is -0.3536. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Beta is -0.3536 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €20.60 is trading 14.9% below its estimated GF Value™ of €24.22.

Key valuation signals for FRA:82P:

  • Beta: -0.3536
  • GF Value™: €24.22 vs. price of €20.60 (14.9% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score

Get the complete analysis for FRA:82P

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.60
Price
€24.22
GF Value